Repligen (RGEN) Tops Q4 EPS by 10c, Guidance Falls Short of Conensus

Repligen (NASDAQ: RGEN) reported Q4 EPS of $0.68, $0.10 better than the analyst estimate of $0.58. Revenue for the quarter came in at $186.8 million versus the consensus estimate of $186.3 million.

GUIDANCE:

Repligen sees FY2023 EPS of $2.61-$2.69, versus the consensus of $2.92. Repligen sees FY2023 revenue of $760-800 million, versus the consensus of $800 million.

For earnings history and earnings-related data on Repligen (RGEN) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Endava CFO placed on leave amid accounting probe
• Jefferies Starts Oversea-Chinese Banking Corp Ltd (OCBC:SP) (OVCHF) at Hold